Research Article
Predictive Value of 1-Hour Glucose Elevations during Oral Glucose Tolerance Testing for Cystic Fibrosis-Related Diabetes
Table 1
Baseline demographics for the cross-sectional and longitudinal cohorts.
| | | Group 1 (cross-sectional cohort) | Group 2 (longitudinal cohort) | | n = 243 | n = 177 |
| | Male, n (%) | 120 (49%) | 94 (53%) | | Race | | Caucasian, n (%) | 194 (80%) | 142 (80%) | | Other, n (%) | 49 (20%) | 35 (20%) | | Age (years) | 12.66 ± 3.03 | 12.42 ± 2.58 | | Fasting OGTT (mg/dL) | 89 ± 8 | 89 ± 8 | | 1-hour glucose (mg/dL) | 163 ± 45 | 162 ± 45 | | 2-hour glucose (mg/dL) | 117 ± 33 | 116 ± 33 | | BMI%ile | 18.77 ± 2.95 | 19.01 ± 3.05 | | HbA1c (%) | 5.5 ± 0.4 | 5.5 ± 0.4 | | Genotype, n (%) | | Residual function mutations | 22 (9%) | 14 (8%) | | 2 minimal function mutations | 213 (88%) | 159 (90%) | | Unknown | 8 (3%) | 4 (2%) | | FEV1% predicted | 91.64 ± 16.88 | 90.69 ± 15.71 | | FVC% predicted | 99.13 ± 14.98 | 98.29 ± 13.67 | | FEV1/FVC | 0.92 ± 0.09 | 0.92 ± 0.08 | | CFTR modulator use at baseline, n (%) | | Yes | 42 (17%) | 21 (12%) | | No | 201 (83%) | 156 (88%) | | Started on modulator during follow-up, n (%) | | Yes | 90 (37%) | 79 (45%) | | No | 153 (63%) | 98 (55%) |
|
|
